DENGVAXIA (PF) (dengue tetravalent vaccine, live, vero cell/PF)
DENGUE VACCINE · DENGUE VACCINATION
SANOFI-PASTEUR
Drug class
Dengue Vaccine
The dengue vaccine class comprises active immunizing biological agents developed to prevent dengue disease and reduce severe complications caused by the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Read more about Dengue Vaccine
2 drugs in this class 1 manufacturers
Drugs in Dengue Vaccine
DENGVAXIA (dengue tetravalent vaccine, live, vero cell/PF)
DENGUE VACCINE · DENGUE VACCINATION
SANOFI-PASTEUR
Filter & compare in the drug finder →
Opens the drug finder with Dengue Vaccine preselected. Add indication or manufacturer filters there.
The dengue vaccine class comprises active immunizing biological agents developed to prevent dengue disease and reduce severe complications caused by the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).
Primarily formulated as live-attenuated tetravalent vaccines—such as chimeric yellow fever–dengue or recombinant attenuated dengue backbones—these agents elicit neutralizing antibody and cellular immune responses against all four viral serotypes.
Clinically, they are indicated for the prevention of symptomatic infection, hospitalization, and severe dengue manifestations, particularly dengue hemorrhagic fever and dengue shock syndrome, in populations living in or traveling to endemic regions.
Because serostatus significantly influences vaccine safety and efficacy profiles, use within this class often depends on prior exposure to minimize risks of vaccine-induced disease enhancement.
-
fda.gov
The dengue vaccine class comprises active immunizing biological agents developed to prevent dengue disease and reduce severe complications caused by the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) Clinically, they are indicated for the prevention of symptomatic infection, hospitalization, and severe dengue manifestations, particularly dengue hemorrhagic fever and dengue shock syndrome, in populations living in or traveling to endemic regions Because serostatus significantly ...
-
cdc.gov
Primarily formulated as live-attenuated tetravalent vaccines—such as chimeric yellow fever–dengue or recombinant attenuated dengue backbones—these agents elicit neutralizing antibody and cellular immune responses against all four viral serotypes
-
fda.gov
Primarily formulated as live-attenuated tetravalent vaccines—such as chimeric yellow fever–dengue or recombinant attenuated dengue backbones—these agents elicit neutralizing antibody and cellular immune responses against all four viral serotypes
-
mednexus.org
Primarily formulated as live-attenuated tetravalent vaccines—such as chimeric yellow fever–dengue or recombinant attenuated dengue backbones—these agents elicit neutralizing antibody and cellular immune responses against all four viral serotypes
-
who.int
Clinically, they are indicated for the prevention of symptomatic infection, hospitalization, and severe dengue manifestations, particularly dengue hemorrhagic fever and dengue shock syndrome, in populations living in or traveling to endemic regions
-
takeda.com
Clinically, they are indicated for the prevention of symptomatic infection, hospitalization, and severe dengue manifestations, particularly dengue hemorrhagic fever and dengue shock syndrome, in populations living in or traveling to endemic regions Because serostatus significantly influences vaccine safety and efficacy profiles, use within this class often depends on prior exposure to minimize risks of vaccine-induced disease enhancement
-
sanofi.com
Because serostatus significantly influences vaccine safety and efficacy profiles, use within this class often depends on prior exposure to minimize risks of vaccine-induced disease enhancement
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.